1. Report Overview

1.1 Global Rheumatoid Arthritis Drugs Market Overview

1.2 Overview of Findings

1.3 Structure of the Report

1.4 Global Rheumatoid Arthritis Drugs Market Segmentation

1.5 Why You Should Read This Report

1.6 How This Report Delivers

1.7 Key Questions Answered by This Analytical Report

1.8. Who is This Report For?

1.9 Methodology

1.10 Associated Visiongain Reports

1.11 About Visiongain

2. Introduction to Rheumatoid Arthritis Drugs

2.1 What is Rheumatoid Arthritis?

2.2 What Causes Rheumatoid Arthritis?

2.3. How Does the Disease Develop?

2.4. How Can It Be Monitored?

2.5. Can RA Be Cured?

2.6. Performance Criteria Used in Clinical Trials

2.6.1. ACR Criteria for Drug Efficacy

2.6.2. HAQ-DI Measures Daily Activities

2.6.3. mSS Assesses Disease on X-Ray

2.6.4. DAS28 For Disease Severity

2.7. How is RA Treated?

2.7.1 Biologic DMARDs Are the Dominant Source of Revenue

2.7.2 Synthetic DMARDs are the Mainstay of Treatment

2.7.3 Others

2.7.3.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

2.7.3.2 Corticosteroids for Rapid Anti-Inflammatory Effect

2.7.3.3 Analgesics for Rapid Pain Relief

2.8 Comorbid Conditions Associated with RA

2.9 Prevalence and Incidence Rates of Rheumatoid Arthritis

3. Rheumatoid Arthritis Drugs Market, 2020-2030

3.1 The Global Rheumatoid Arthritis Drugs Market: Market Overview

3.2 Global Rheumatoid Arthritis Drugs Market: Revenue Forecast 2020-2030

3.3 Global Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

3.4 Changing Market Shares by Segment 2020-2030

3.5 Non-Biologics for RA

3.5.1 NSAIDs: Revenue Forecast, 2020-2030

3.5.2 Synthetic DMARDs (sDMARDs): Revenue Forecast, 2018-2030

3.5.3 Others: Revenue Forecast, 2018-2030

4. Leading Drugs in the Rheumatoid Arthritis Market 2020-2030

4.1 The Main Drugs in the Rheumatoid Arthritis Market, 2018

4.2 Humira: A Major Source of Revenue for AbbVie

4.2.1 Adalimumab Biosimilars

4.2.2 Humira: Sales Forecast 2020-2030

4.3 Enbrel: Amgen’s Revenue Protected Until 2030

4.3.1 Etanercept Biosimilars

4.3.2 Enbrel: Revenue Forecast 2020-2030

4.4 Remicade: Facing Significant Competition from Biosimilars

4.4.1 Infliximab Biosimilars

4.4.2 Remicade: Revenue Forecast 2018-2030

4.5 Rituxan: Facing Declining Market Share

4.5.1 Rituximab Biosimilars

4.5.2 Rituxan: Revenue Forecast 2018-2030

4.6 Simponi (golimumab): Market Share Remaining Stable

4.6.1 Simponi/Simponi Aria: Revenue Forecast 2018-2030

4.7 Orencia: Additional Indications Being Explored

4.7.1 Abatacept Biosimilars

4.7.2 Orencia: Revenue Forecast 2018-2030

4.8 Actemra/RoActemra: First IL-6R Inhibitor Approved for RA

4.8.1 Tocilizumab Biosimilars

4.8.2 Actemra/RoActemra: Revenue Forecast 2018-2030

4.9 Cimzia: Reliable Source of Income for UCB

4.9.1 Certolizumab Biosimilars

4.9.2 Cimzia: Revenue Forecast 2018-2030

4.10 Celebrex: Facing Generic Competition

4.10.1 Celebrex: Revenue Forecast 2018-2030

4.11 Xeljanz: Good Opportunity for Revenue Growth

4.11.1 Xeljanz: Revenue Forecast 2018-2030

4.12 Arcoxia: Sales Revenue Already Declining

4.12.1 Arcoxia: Revenue Forecast 2018-2030

5. Leading National Markets 2020-2030

5.1. Geographical Breakdown of the World Rheumatoid Arthritis Drugs Market

5.2 World Rheumatoid Arthritis Drugs Market: Regional Forecast 2020-2030

5.2.1 How Will Regional Market Shares Change to 2030?

6. North America Rheumatoid Arthritis Drugs Market, 2020-2030

6.1. US Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

6.2. Canada Rheumatoid Arthritis Drugs Market: Trends and Developments

7. Europe Rheumatoid Arthritis Drugs Market 2020-2030

7.1 Europe Markets: Changing Market Shares by Country, 2020-2030

7.2. Germany Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

7.3. France Rheumatoid Arthritis Drugs Market: Trends and Developments

7.4. U.K. Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

7.5. Italy Rheumatoid Arthritis Drugs Market: Trends and Developments

7.6. Spain Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

7.7. Russia Rheumatoid Arthritis Drugs Market: Trends and Developments

7.8. Rest of Europe Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

8. Asia-Pacific Rheumatoid Arthritis Drugs Market 2020-2030

8.1. Japan Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

8.2. China Rheumatoid Arthritis Drugs Market: Trends and Developments

8.3. India Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

8.4. Rest of Asia Pacific Rheumatoid Arthritis Drugs Market: Trends and Developments

9. Latin America Rheumatoid Arthritis Drugs Market, 2020-2030

9.1. Brazil Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

9.2. Mexico Rheumatoid Arthritis Drugs Market: Trends and Developments

9.3. Rest of Latin America Rheumatoid Arthritis Drugs Market: Trends and Developments

10. Middle East & Africa Rheumatoid Arthritis Drugs Market, 2020-2030

10.1. Saudi Arabia Rheumatoid Arthritis Drugs Market: Market Forecast 2020-2030

10.2. South Africa Rheumatoid Arthritis Drugs Market: Trends and Developments

10.3. Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market: Trends and Developments

11. Rheumatoid Arthritis R&D Pipeline 2019

12. Leading Companies in the Rheumatoid Arthritis Drugs Market, 2019

12.1 Introduction to the Leading Companies

12.2 AbbVie: Secured Multiple Patents for Humira

12.2.1 Overview

12.2.2 AbbVie: Rheumatoid Arthritis Drugs Product Portfolio

11.2.3 AbbVie: Financial Overview

12.2.4 AbbVie: Recent Transactions Summary

12.3 F. Hoffmann-La Roche Ltd (Roche)

12.3.1 Overview

12.3.2 Roche: Financial Overview

12.3.3 Recent Transactions Summary

12.4 Johnson & Johnson

12.4.1 Overview

12.4.2 Johnson & Johnson: Financial Overview

12.4.3 Johnson & Johnson: Recent Transactions Summary

11.5. Amgen, Inc.

12.5.1 Overview

12.5.2 Amgen Inc.: Financial Overview

12.5.3. Amgen Inc.: Recent Transactions Summary

12.6. Pfizer: Actively Developing Biosimilars

12.6.1 Overview

12.6.2 Pfizer, Inc.: Financial Overview

12.6.3 Pfizer, Inc.: Recent Transactions Summary

12.7 Merck & Co., Inc.: Remicade Sales in Decline

12.7.1. Overview

12.7.2 Merck & Co., Inc.: Financial Overview

12.7.3 Merck & Co., Inc.: Recent Transactions Summary

12.8. Bristol-Myers Squibb (BMS): Exploring Additional Indications for Orencia

12.8.1. Overview

12.8.2 Bristol-Myers Squibb: Financial Overview

12.8.3 Bristol-Myers Squibb: Recent Developments

12.9. UCB: Reliant on Cimzia Revenue

12.9.1 Overview

12.9.2 UCB: Financial Overview

12.9.3 UCB: Recent Developments

12.10. Eli Lilly and Company

12.10.1 Eli Lilly and Company: Rheumatoid Arthritis Drugs Portfolio

12.10.2 Eli Lilly and Company: Financial Overview

12.10.3 Eli Lilly and Company: Recent Transactions Summary

12.11. Novartis AG

12.11.1 Novartis AG: Rheumatoid Arthritis Drugs Portfolio

12.11.2 Novartis AG: Financial Overview

12.11.3 Novartis AG: Recent Transactions Summary

12.12. Sanofi S.A. (Sanofi)

12.12.1 Sanofi S.A.: Rheumatoid Arthritis Drugs Portfolio

12.12.2 Sanofi: Financial Overview

12.12.3 Sanofi S.A.: Recent Transactions Summary

13. Qualitative Analysis of the Rheumatoid Arthritis Market

13.1 Strengths and Weaknesses of the Rheumatoid Arthritis Market

13.1.1 Strengths

13.1.1.1 Number of Elderly Patients Expected to Rise

13.1.1.2 Biologics Already Recognised as a Valuable Part of Treatment

13.1.1.3 Biologics Used in RA Often Have Multiple Indications

13.1.2 Weaknesses

13.1.2.1 Some Patients Have an Inadequate Treatment Response

13.1.2.2. Efficacy of Drugs Can Diminish Over Time

13.1.3. Opportunities

13.1.3.1 Need for Effective Drugs with Better Safety Profiles

13.1.3.2 Need for Less Invasive Route of Administration

13.1.4. Threats

13.1.4.1 High Number of Products Will Saturate Market

13.1.4.2 Competition from Biosimilars Will Increase

13.2 Social, Technological, Economic and Political Factors Affecting the Rheumatoid Arthritis Market (STEP Analysis)

13.2.1 Social Factors Influencing the Rheumatoid Arthritis Market

13.2.2 Technological Factors Influencing the Rheumatoid Arthritis Market

13.2.3 Economic Factors Influencing the Rheumatoid Arthritis Market

13.2.4 Political Factors Influencing the Rheumatoid Arthritis Market

13.2.4.1 Government Pressure to Control Costs

13.2.4.2 Inter-country Variability in Biosimilar Approval Process

14. Conclusions

14.1 Overview of Current Market Conditions and Market Forecast

14.2 Biologics Will Remain Dominant Drug Class but their Market Share Will Drop More than 20%

14.3 Enbrel Will Overtake Humira as the Leading Drug

14.4 Leading Regions in the Rheumatoid Arthritis Market in 2018

14.5 Trends in the RA Drugs Market

Appendices

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Visiongain Report Evaluation Form

List of Table

Table 2.1 Biologic Agents and Mechanism of Action

Table 2.2 Comorbidities Associated with RA in Different Organs

Table 2.3 Prevalence rate of RA in Different Countries

Table 3.1 Rheumatoid Arthritis Drugs Market by Submarket, 2018

Table 3.2 The Global Rheumatoid Arthritis Drugs Market: Revenue ($m) and Market Shares (%) by Type, 2018 and 2019

Table 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 3.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 3.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: CAGR (%), 2020-

2024, 2024-2030, 2020-2030

Table 3.6 Non-Biologics for Rheumatoid Arthritis Market Forecast: Revenues ($m), AGR

(%), CAGR (%), 2018-2030

Table 3.7 NSAIDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%)

and CAGR (%), 2018-2030

Table 3.8 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%)

and CAGR (%), 2018-2030

Table 3.9 Others for Rheumatoid Arthritis Forecasts: Revenue ($m), AGR (%) and CAGR

(%), 2018-2030

Table 4.1 Global Rheumatoid Arthritis Market by Drugs Classs: Revenue ($m), and

Market Share (%), 2018

Table 4.2 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue

($m), AGR (%) and CAGR (%), 2018-2030

Table 4.3 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030

Table 4.4 The Main Drugs in the Rheumatoid Arthritis Market Forecasts: Revenue ($m), AGR (%) and CAGR (%), 2018-2030

Table 4.5 Humira: Key Facts

Table 4.6 Adalimumab Biosimilars: Current Status, 2019

Table 4.7 Global Humira Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.8 Enbrel: Key Facts

Table 4.9 Etanercept Biosimilars: Current Status, 2019

Table 4.10 Global Enbrel Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-

2030

Table 4.11 Remicade: Key Facts

Table 4.12 Infliximab Biosimilars: Current Status, 2019

Table 4.13 Global Remicade Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.14 Rituxan: Key Facts

Table 4.15 Rituximab Biosimilars: Current Status, 2019

Table 4.16 Global Rituxan Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.17 Simponi: Key Facts

Table 4.18 Global Simponi/Simponi Aria Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.19 Orencia: Key Facts

Table 4.20 Global Orencia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.21 Actemra/RoActemra: Key Facts

Table 4.22 Global Actemra/RoActemra Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.23 Cimzia: Key Facts

Table 4.24 Global Cimzia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.25 Celebrex: Key Facts

Table 4.26 Global Celebrex Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.27 Xeljanz: Key Facts

Table 4.28 Global Xeljanz Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 4.29 Arcoxia: Key Facts

Table 4.30 Global Arcoxia Market Forecast: Revenues ($m) AGR (%), CAGR (%), 2018-2030

Table 5.1 Global Rheumatoid Arthritis Drugs Market by Region: Revenue ($ m), 2018 and

2019

Table 5.2 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m), AGR (%),

CAGR (%), 2018-2030

Table 5.3 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024,

2024-2030, 2020-2030

Table 5.4 Global Rheumatoid Arthritis Drugs Market by Region: Market Share (%), 2019, 2024, 2030

Table 6.1 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 6.2 North America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by

Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 6.3 North America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues

($ m), AGR (%), CAGR (%), 2018-2030

Table 6.4 U.S.Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 6.5 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR

(%), CAGR (%), 2018-2030

Table 7.1 Europe Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue

($m) and Market Share (%), 2018

Table 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m),

AGR (%), CAGR (%), 2018-2030

Table 7.3 Europe Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by

Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 7.4 Global Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 7.5 Europe Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues ($m),

AGR (%), CAGR (%), 2018-2030

Table 7.6 Global Rheumatoid Arthritis Drugs Market by Region: CAGR (%), 2020-2024,

2024-2030, and 2020-2030

Table 7.7 Germany Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($

m), AGR (%), CAGR (%), 2018-2030

Table 7.8 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 7.9 U.K.Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m),

AGR (%), CAGR (%), 2018-2030

Table 7.10 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 7.11 Spain Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 7.12 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR

(%), CAGR (%), 2018-2030

Table 7.13 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast by Country:

Revenues ($ m), AGR (%), CAGR (%), 2018-2030

Table 8.1 Global Rheumatoid Arthritis Drugs Market by Country/Sub-region: Revenue ($

m) and Market Share (%), 2018

Table 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 8.3 Asia Pacific Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by

Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 8.4 Asia-Pacific Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 8.5 Japan Rheumatoid Arthritis Drugs Market Forecast by Country: Revenues ($m),

AGR (%), CAGR (%), 2018-2030

Table 8.6 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 8.7 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 8.8 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 9.1 Latin America Rheumatoid Arthritis Drugs Market by Country/Sub-region:

Revenue ($m) and Market Share (%), 2018

Table 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast by Class: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 9.3 Latin America Rheumatoid Arthritis Drugs (Non-Biologics) Market Forecast by

Segment: Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 9.4 Latin America Rheumatoid Arthritis Drugs Market Forecast by Country:

Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 9.5 Brazil Rheumatoid Arthritis Drugs Market Forecast, By Country: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 9.6 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%),

CAGR (%), 2018-2030

Table 9.7 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues

($m), AGR (%), CAGR (%), 2018-2030

Table 10.1 Middle East & Africa Rheumatoid Arthritis Drugs Market by Country/Sub-

region: Revenue ($ m) and Market Share (%), 2018

Table 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Class:

Revenues ($ m), AGR (%), CAGR (%), 2018-2030

Table 10.3 Middle East & Africa Rheumatoid Arthritis Drugs (Non-Biologics) Market

Forecast by Segment: Revenues ($ m), AGR (%), CAGR (%), 2018-2030

Table 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast by Country:

Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 10.5 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast by Country:

Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 10.6 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($ m),

AGR (%), CAGR (%), 2018-2030

Table 10.7 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast:

Revenues ($m), AGR (%), CAGR (%), 2018-2030

Table 11.1 Pipeline R&D Products, 2019

Table 11.2 Other RA Pipeline R&D Products, 2019

Table 12.1 Leading Companies in the RA Drug Market: Revenue ($m) and Market Share

(%), 2018

Table 12.2 AbbVie: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.3 AbbVie: Overview, 2019

Table 12.4 AbbVie: Revenue ($m), AGR (%), 2014-2018

Table 12.5 F.Hoffmann-La Roche AG:: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.6. Roche: Overview, 2019

Table 12.7 Roche: Revenue ($m), AGR (%), 2014-2018

Table 12.8 Johnson & Johnson: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.9. Johnson & Johnson: Overview, 2019

Table 12.10 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018

Table 12.11 Amgen: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.12 Amgen, Inc.: Overview, 2019

Table 12.13 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018

Table 12.14 Pfizer: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.15 Pfizer, Inc.: Overview, 2019

Table 12.16 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018

Table 12.17 Merck & Co., Inc.: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.18 Merck & Co., Inc.: Overview, 2019

Table 12.19 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018

Table 12.20 Bristol-Myers Squibb: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.21 Bristol-Myers Squibb: Overview, 2019

Table 12.22 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018

Table 12.23 UCB: Breakdown of Revenue ($m,%) by RA Drug, 2018

Table 12.24 UCB: Overview, 2019

Table 12.25 UCB: Revenue ($m), AGR (%), 2014-2018

Table 12.26 Eli Lilly and Company: Overview, 2019

Table 12.27 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018

Table 12.28 Novartis AG: Overview, 2019

Table 12.29 Novartis AG: Revenue ($m), AGR (%), 2014-2018

Table 12.30 Sanofi S.A.: Overview, 2019

Table 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018

Table 13.1 SWOT Analysis of the Global Rheumatoid Arthritis Market, 2020-2030

Table 13.2 Social, Technological, Economic and Political Factors Influencing the RA

Market, 2018-2030

Table 14.1 Global Rheumatoid Arthritis Market Forecast: Revenue ($m), and CAGR (%),

2018, 2024 and 2030

Table 14.2 Global Rheumatoid Arthritis Market by Drugs Class: CAGR (%), 2018, 2024,

2030

Table 14.3 Global Rheumatoid Arthritis Market by Region: CAGR (%), 2018, 2024, 2030

List of Figure

Figure 1.1 Global Rheumatoid Arthritis Drugs Market Segmentation Overview

Figure 3.1 Rheumatoid Arthritis Drugs Market: Market Share (%) by Indication, 2018

Figure 3.2 Rheumatoid Arthritis Drugs Market: Market Share (%) by Class, 2018

Figure 3.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030

Figure 3.4 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2018

Figure 3.5 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class, 2019

Figure 3.6 The Global Rheumatoid Arthritis Drugs Market Forecast by Drugs Class: CAGR (%), 2020-2030

Figure 3.7 The Rheumatoid Arthritis Drugs Market Segments: Revenue ($m) Forecast, 2018-2030

Figure 3.8 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018

Figure 3.9 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024

Figure 3.10 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030

Figure 3.11 Non-Biologics for Rheumatoid Arthritis: Revenue ($m) Forecasts by Segment, 2018-2030

Figure 3.12 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2018

Figure 3.13 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2024

Figure 3.14 Non-Biologics for Rheumatoid Arthritis: Market Share (%), 2030

Figure 3.15 Global NSAIDs Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030

Figure 3.16 sDMARDs for Rheumatoid Arthritis Market Forecasts: Revenue ($ m), AGR (%), 2018-2030

Figure 3.17 Others Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030

Figure 4.1 The Main Drugs in the Rheumatoid Arthritis Market: Market Shares (%), 2018

Figure 4.2 Global Humira Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.3 Global Enbrel Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.4 Global Remicade Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.5 Global Rituxan Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.6 Global Simponi/Simponi Aria Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.7 Global Orencia Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.8 Global Actemra/RoActemra Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.9 Global Cimzia Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.10 Global Celebrex Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.11 Global Xeljanz Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 4.12 Global Arcoxia Market Forecast: Revenue ($m) AGR (%), 2018-2030

Figure 5.1 World Rheumatoid Arthritis Drugs Market: Revenues ($ m) by Region, 2018

Figure 5.2 World Rheumatoid Arthritis Drugs Market: Revenues ($m) by Region, 2019

Figure 5.3 Global Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030

Figure 5.4 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019

Figure 5.5 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024

Figure 5.6 World Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030

Figure 6.1 North America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030

Figure 6.2 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2019

Figure 6.3 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2024

Figure 6.4 North America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Regional Market, 2030

Figure 6.5 U.S. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 6.6 Canada Rheumatoid Arthritis Drugs Market Forecast: Revenues($m), AGR (%), 2018-2030

Figure 7.1 Europe Rheumatoid Arthritis Drugs Market: Revenues ($m) by

Country/Sub-region, 2018

Figure 7.2 Europe Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030

Figure 7.3 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018

Figure 7.4 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024

Figure 7.5 Europe Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030

Figure 7.6 Germany Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.7 France Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.8 U.K. Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.9 Italy Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.10 Spain Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.11 Russia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 7.12 Rest of Europe Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 8.1 Asia Pacific Rheumatoid Arthritis Drugs Market: Revenues ($m) by

Country/Sub-region, 2018

Figure 8.2 Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenue ($ m), AGR (%), 2018-2030

Figure 8.3 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018

Figure 8.4 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024

Figure 8.5 Asia Pacific Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030

Figure 8.6 Japan Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 8.7 China Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 8.8 India Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 8.9 Rest of Asia Pacific Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 9.1 Latin America Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018

Figure 9.2 Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030

Figure 9.3 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018

Figure 9.4 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024

Figure 9.5 Latin America Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030

Figure 9.6 Brazil Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 9.7 Mexico Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 9.6 Rest of Latin America Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 10.1 Middle East & Africa (MEA) Rheumatoid Arthritis Drugs Market: Revenues ($m) by Country/Sub-region, 2018

Figure 10.2 Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenue ($m), AGR (%), 2018-2030

Figure 10.3 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2018

Figure 10.4 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2024

Figure 10.5 Middle East & Africa Rheumatoid Arthritis Drugs Market: Market Shares (%) by Country, 2030

Figure 10.6 Saudi Arabia Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 10.7 South Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 10.8 Rest of Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast: Revenues ($m), AGR (%), 2018-2030

Figure 12.1 AbbVie: Revenue ($m), AGR (%), 2014-2018

Figure 12.2 AbbVie: Business Segment Revenue Share (%), 2018

Figure 12.3 AbbVie: Region Revenue Share (%), 2018

Figure 12.4 Roche: Revenue ($m), AGR (%), 2014-2018

Figure 12.5 Roche: Business Segment Revenue Share (%), 2018

Figure 12.6 Roche: Breakdown of Revenue (%) by Pharmaceuticals Drug, 2018

Figure 12.7 Johnson & Johnson: Revenue ($m), AGR (%), 2014-2018

Figure 12.8 Johnson & Johnson: by Business Segments Revenue Share (%), 2018

Figure 12.9 Johnson & Johnson: by Region Revenue Share (%), 2018

Figure 12.10 Amgen Inc.: Revenue ($m), AGR (%), 2014-2018

Figure 12.11 Amgen Inc.: Business Segment Revenue Share (%), 2018

Figure 12.12 Amgen Inc.: Region Revenue Share (%), 2018

Figure 12.13 Pfizer, Inc.: Revenue ($m), AGR (%), 2014-2018

Figure 12.14 Pfizer, Inc.: Business Segment Revenue Share (%), 2018

Figure 12.15 Pfizer, Inc: Region Revenue Share (%), 2018

Figure 12.16 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018

Figure 12.17 Merck & Co., Inc.: Business Segment Revenue Share (%), 2018

Figure 12.18 Merck & Co., Inc.: by Region Revenue Share (%), 2018

Figure 12.19 Bristol-Myers Squibb: Revenue ($m), AGR (%), 2014-2018

Figure 12.20 Bristol-Myers Squibb: Business Segment Revenue Share (%), 2018

Figure 12.21 Bristol-Myers Squibb: by Region Revenue Share (%), 2018

Figure 12.22 UCB: Revenue ($m), AGR (%), 2014-2018

Figure 12.23 UCB: Business Segment Revenue Share (%), 2018

Figure 12.24 UCB: by Region Revenue Share (%), 2018

Figure 12.25 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018

Figure 12.26 Eli Lilly and Company: Business Segment Revenue Share (%), 2018

Figure 12.27 Eli Lilly and Company: by Region Revenue Share (%), 2018

Figure 12.28 Novartis AG: Revenue ($m), AGR (%), 2014-2018

Figure 12.29 Novartis AG: Business Segment Revenue Share (%), 2018

Figure 12.30 Novartis AG: by Region Revenue Share (%), 2018

Figure 12.31 Sanofi: Revenue ($m), AGR (%), 2014-2018

Figure 12.32 Sanofi: Business Segment Revenue Share (%), 2018

Figure 12.33 Sanofi: by Region Revenue Share (%), 2018

Figure 14.1 RA Drugs Market: Comparison of Revenue ($m Forecasts for Total Market and Market for RA Indication, 2018-2030

Figure 14.2 Global Rheumatoid Arthritis Market Forecast: Revenue ($m) 2018, 2024, 2030

Figure 14.3 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2018

Figure 14.4 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2024

Figure 14.5 Global Rheumatoid Arthritis Drugs Market by Drugs Class: Market Share (%), 2030

Figure 14.6 The Leading Drugs in the RA Market: Revenue ($m) Forecasts, 2018, 2024, 2030

Figure 14.7 The Global Rheumatoid Arthritis Market Forecast by Region: Revenue ($m), 2018, 2024, 2030